Management of first trimester pregnancy loss: mifepristone plus misoprostol versus misoprostol alone
Miscarriage occurs in 20% of all pregnancies. Misoprostol is implemented alone for the medical management of first trimester pregnancy loss in New Zealand and the UK. However, current research reports mifepristone plus misoprostol is significantly more effective than misoprostol alone. Results from current randomised control trials indicate efficacy rates of mifepristone, plus misoprostol range between 73%-89.3% compared to 34.8%-67.1% for misoprostol alone. Further research is recommended to ascertain medication regimes and associated adverse effects. Current guidelines for the medical management of first trimester miscarriage should be reviewed in regards to implementing mifepristone in management pathways.
Miscarriage occurs in 20% of all pregnancies (Fernlund et al, 2018) and medical management using misoprostol is now a popular treatment option as opposed to surgical intervention. Current research indicates the use of mifepristone in combination with misoprostol due to higher efficacy rates with this combination (Tulandi and Al-Fozan, 2018).
Mifepristone is a synthetic steroid which acts as a progesterone antagonist (Im and Appleman, 2010). Progesterone is an important endogenous hormone required for ongoing pregnancy (Dunford and Fyfe, 2018). On a cellular level, mifepristone blocks progesterone uptake leading to decreased levels which initiates uterine contraction, cervical softening, dilation, and sensitising the myometrium to prostaglandins; hormones which support uterine contractility (Im and Appleman, 2010; Medsafe, 2013; Dunford and Fyfe, 2018).
Register now to continue reading
Thank you for visiting British Journal of Midwifery and reading some of our peer-reviewed resources for midwives. To read more, please register today. You’ll enjoy the following great benefits:
Limited access to our clinical or professional articles
New content and clinical newsletter updates each month